← Back to headlines
FDA Approves Priovant's Lisraya for Dermatomyositis Treatment
The U.S. Food and Drug Administration has granted approval to Lisraya, developed by Priovant, marking a new therapeutic option for patients suffering from dermatomyositis.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
